Godavari Drugs

{
  "main_header": {
    "sid": 765253,
    "name": "Godavari Drugs",
    "stock_name": "Godavari Drugs",
    "full_name": "Godavari Drugs Ltd",
    "name_url": "stocks-analysis/godavari-drugs",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 0,
    "country_id": 34,
    "currency": "INR",
    "cmp": "120.00",
    "chg": "0.00",
    "chgp": "0.00%",
    "dir": 0,
    "prev_price": "120.00",
    "mcapval": "126.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 530317,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE362C01012",
    "curr_date": "Jul 17, 03:30 PM",
    "curr_time": "09:22 AM",
    "last_traded_at": "Jul 17, 03:30 PM IST",
    "bse_nse_vol": "2.94 k",
    "exc_status": "Active",
    "traded_date": "Jul 17, 2026",
    "traded_date_str": "2026 07 17",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/godavari-drugs-765253-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Godavari Drugs Ltd Downgraded to Sell Amid Mixed Fundamentals and Technical Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/godavari-drugs-ltd-downgraded-to-sell-amid-mixed-fundamentals-and-technical-signals-4095852",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/GodavariDrugsLt_mojoScore_4095852.png",
        "date": "2026-07-10 08:05:43",
        "description": "Godavari Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 9 July 2026. This decision follows a comprehensive reassessment across four critical parameters: quality, valuation, financial trend, and technicals. Despite delivering market-beating returns over the past year, the company’s deteriorating fundamentals and mixed technical signals have prompted a cautious stance from analysts."
      },
      {
        "title": "Godavari Drugs Ltd Upgraded to Hold on Technical Improvements and Valuation Appeal",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/godavari-drugs-ltd-upgraded-to-hold-on-technical-improvements-and-valuation-appeal-4090116",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/GodavariDrugsLt_mojoScore_4090116.png",
        "date": "2026-07-06 08:04:55",
        "description": "Godavari Drugs Ltd has seen its investment rating upgraded from Sell to Hold as of 3 July 2026, reflecting a notable improvement in its technical indicators and valuation metrics despite flat recent financial performance. The pharmaceutical company’s stock has outperformed the broader market over the past year, prompting a reassessment of its prospects across quality, valuation, financial trend, and technical parameters."
      },
      {
        "title": "Godavari Drugs Ltd Downgraded to Sell Amid Mixed Financial and Technical Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/godavari-drugs-ltd-downgraded-to-sell-amid-mixed-financial-and-technical-signals-4068333",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/GodavariDrugsLt_mojoScore_4068333.png",
        "date": "2026-06-23 08:17:24",
        "description": "Godavari Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 22 June 2026. This change reflects a complex interplay of technical indicators, valuation metrics, financial trends, and quality assessments that collectively signal caution for investors despite some market-beating returns over the past year."
      },
      {
        "title": "Godavari Drugs Ltd Upgraded to Hold on Technical and Valuation Improvements",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/godavari-drugs-ltd-upgraded-to-hold-on-technical-and-valuation-improvements-4058337",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/GodavariDrugsLt_mojoScore_4058337.png",
        "date": "2026-06-17 08:10:09",
        "description": "Godavari Drugs Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a notable improvement in its technical indicators and valuation metrics despite ongoing challenges in financial performance. The upgrade, effective from 16 June 2026, is driven primarily by enhanced technical trends, attractive valuation ratios, and increased institutional participation, positioning the micro-cap pharmaceutical firm for cautious optimism amid a mixed fundamental backdrop."
      },
      {
        "title": "Godavari Drugs Ltd Downgraded to Sell Amid Mixed Fundamentals and Technical Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/godavari-drugs-ltd-downgraded-to-sell-amid-mixed-fundamentals-and-technical-signals-4048437",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/GodavariDrugsLt_mojoScore_4048437.png",
        "date": "2026-06-12 08:06:52",
        "description": "Godavari Drugs Ltd has seen its investment rating downgraded from Hold to Sell as of 11 June 2026, reflecting a complex interplay of technical, valuation, financial trend, and quality factors. Despite a strong year-to-date return of 50.98%, the company’s deteriorating fundamentals and mixed technical signals have prompted a reassessment of its outlook within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Godavari Drugs Gains 0.28%: 2 Key Events Shaping This Week’s Movement",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/godavari-drugs-gains-028-2-key-events-shaping-this-weeks-movement-4023156",
        "imagepath": "",
        "date": "2026-05-30 15:04:55",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>25 May:</strong> Stock opens at Rs.126.95, modest gain of 0.16%</p>\n                    <p><strong>26 May:</strong> Strong rally with 1.54% gain despite Sensex decline</p>\n                    <p><strong>27 May:</strong> New 52-week high reached at Rs.135.25</p>\n                    <p><strong>29 May:</strong> Q4 FY26 results released; stock closes lower at Rs.127.10 (-2.23%)</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\">\n                        <div class=\"stat-label\">Week Open</div>\n                        <div class=\"stat-value\">Rs.126.75</div>\n                    </div>\n                    <div class=\"stat-item\">\n ..."
      },
      {
        "title": "Are Godavari Drugs Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-godavari-drugs-ltd-latest-results-good-or-bad-4021796",
        "imagepath": "",
        "date": "2026-05-29 19:39:39",
        "description": "Godavari Drugs Ltd has reported its financial results for Q4 FY26, showcasing a significant quarter-on-quarter increase in both net sales and net profit. Specifically, net sales reached ₹33.16 crores, reflecting a growth of 49.50% compared to the previous quarter, which had seen a decline. The net profit for the same quarter was ₹1.29 crores, marking a 69.66% increase from the prior quarter's profit of ₹0.76 crores. This quarter also saw the company achieving its highest-ever quarterly net sales, reversing a trend of three consecutive quarters of volatile performance.\n\nHowever, the operational metrics reveal some challenges. The operating margin, excluding other income, contracted to 8.84%, down from 11.14% in the previous quarter, indicating that the revenue growth may have come at the expense of operational efficiency. Additionally, the return on equity (ROE) stands at 8.82%, which is below industry stand..."
      },
      {
        "title": "Godavari Drugs Ltd is Rated Hold",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/godavari-drugs-ltd-is-rated-hold-4019857",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/GodavariDrugsLt_mojoScore_4019857.png",
        "date": "2026-05-29 10:11:03",
        "description": "Godavari Drugs Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 13 Apr 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 29 May 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Godavari Drugs Q4 FY26: Strong Quarter Masks Deeper Concerns About Long-Term Growth",
        "link": "https://www.marketsmojo.com/news/result-analysis/godavari-drugs-q4-fy26-strong-quarter-masks-deeper-concerns-about-long-term-growth-4020734",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/GodavariDrugs_quaterlyResult_4020734.png",
        "date": "2026-05-29 09:44:34",
        "description": "Godavari Drugs Ltd., a micro-cap active pharmaceutical ingredients (API) manufacturer, reported a robust performance in Q4 FY26 with net profit surging 69.66% quarter-on-quarter to ₹1.29 crores, whilst revenue jumped an impressive 49.50% to ₹33.16 crores. However, the positive quarterly momentum stands in stark contrast to the company's troubling five-year track record of negative sales growth and deteriorating operational efficiency, raising critical questions about the sustainability of this recent upturn."
      }
    ],
    "total": 188,
    "sid": "765253",
    "stock_news_url": "https://www.marketsmojo.com/news/godavari-drugs-765253"
  },
  "announcements": [
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "11-Jul-2026",
      "details": "Certificate under Regulation 74(5) of SEBI (Depository and Participants) Regulations 2018",
      "source": "BSE"
    },
    {
      "caption": "Closure of Trading Window",
      "datetime": "23-Jun-2026",
      "details": "Intimation of Closure of Trading window for the quarter ended June 30 2026",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "28-May-2026",
      "details": "Please find the enclosed newspaper publication for your information",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Godavari Drugs Ltd Downgraded to Sell Amid Mixed Fundamentals and Technical Signals

2026-07-10 08:05:43

Godavari Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 9 July 2026. This decision follows a comprehensive reassessment across four critical parameters: quality, valuation, financial trend, and technicals. Despite delivering market-beating returns over the past year, the company’s deteriorating fundamentals and mixed technical signals have prompted a cautious stance from analysts.

Read full news article

Godavari Drugs Ltd Upgraded to Hold on Technical Improvements and Valuation Appeal

2026-07-06 08:04:55

Godavari Drugs Ltd has seen its investment rating upgraded from Sell to Hold as of 3 July 2026, reflecting a notable improvement in its technical indicators and valuation metrics despite flat recent financial performance. The pharmaceutical company’s stock has outperformed the broader market over the past year, prompting a reassessment of its prospects across quality, valuation, financial trend, and technical parameters.

Read full news article

Godavari Drugs Ltd Downgraded to Sell Amid Mixed Financial and Technical Signals

2026-06-23 08:17:24

Godavari Drugs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 22 June 2026. This change reflects a complex interplay of technical indicators, valuation metrics, financial trends, and quality assessments that collectively signal caution for investors despite some market-beating returns over the past year.

Read full news article

Godavari Drugs Ltd Upgraded to Hold on Technical and Valuation Improvements

2026-06-17 08:10:09

Godavari Drugs Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a notable improvement in its technical indicators and valuation metrics despite ongoing challenges in financial performance. The upgrade, effective from 16 June 2026, is driven primarily by enhanced technical trends, attractive valuation ratios, and increased institutional participation, positioning the micro-cap pharmaceutical firm for cautious optimism amid a mixed fundamental backdrop.

Read full news article

Godavari Drugs Ltd Downgraded to Sell Amid Mixed Fundamentals and Technical Signals

2026-06-12 08:06:52

Godavari Drugs Ltd has seen its investment rating downgraded from Hold to Sell as of 11 June 2026, reflecting a complex interplay of technical, valuation, financial trend, and quality factors. Despite a strong year-to-date return of 50.98%, the company’s deteriorating fundamentals and mixed technical signals have prompted a reassessment of its outlook within the Pharmaceuticals & Biotechnology sector.

Read full news article

Godavari Drugs Gains 0.28%: 2 Key Events Shaping This Week’s Movement

2026-05-30 15:04:55

Key Events This Week

25 May: Stock opens at Rs.126.95, modest gain of 0.16%

26 May: Strong rally with 1.54% gain despite Sensex decline

27 May: New 52-week high reached at Rs.135.25

29 May: Q4 FY26 results released; stock closes lower at Rs.127.10 (-2.23%)

Week Open

Rs.126.75

...

Read full news article

Are Godavari Drugs Ltd latest results good or bad?

2026-05-29 19:39:39

Godavari Drugs Ltd has reported its financial results for Q4 FY26, showcasing a significant quarter-on-quarter increase in both net sales and net profit. Specifically, net sales reached ₹33.16 crores, reflecting a growth of 49.50% compared to the previous quarter, which had seen a decline. The net profit for the same quarter was ₹1.29 crores, marking a 69.66% increase from the prior quarter's profit of ₹0.76 crores. This quarter also saw the company achieving its highest-ever quarterly net sales, reversing a trend of three consecutive quarters of volatile performance. However, the operational metrics reveal some challenges. The operating margin, excluding other income, contracted to 8.84%, down from 11.14% in the previous quarter, indicating that the revenue growth may have come at the expense of operational efficiency. Additionally, the return on equity (ROE) stands at 8.82%, which is below industry stand...

Read full news article

Godavari Drugs Ltd is Rated Hold

2026-05-29 10:11:03

Godavari Drugs Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 13 Apr 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 29 May 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Godavari Drugs Q4 FY26: Strong Quarter Masks Deeper Concerns About Long-Term Growth

2026-05-29 09:44:34

Godavari Drugs Ltd., a micro-cap active pharmaceutical ingredients (API) manufacturer, reported a robust performance in Q4 FY26 with net profit surging 69.66% quarter-on-quarter to ₹1.29 crores, whilst revenue jumped an impressive 49.50% to ₹33.16 crores. However, the positive quarterly momentum stands in stark contrast to the company's troubling five-year track record of negative sales growth and deteriorating operational efficiency, raising critical questions about the sustainability of this recent upturn.

Read full news article

View All News